Medical Arrangement Strategies for Infertility Female Patients during COVID-19 Mini-Outbreak

Document Type : Short Communication


1 Reproductive Medical Center, The First Hospital of Lanzhou University, Lanzhou, China

2 Key Laboratory for Reproductive Medicine and Embryo of Gansu Province, Lanzhou, China

3 PET-CT Center of Gansu Provincial Hospital, Lanzhou, China


Over the past two years, COVID-19 pandemic is an unprecedented health emergency. All countries have taken their
own measures to mitigate the spread of the virus in the first and subsequent mini-outbreaks of infection. In view of the
current situation of small outbreaks of COVID-19, guidelines on epidemic prevention should be developed specifically
for reproductive medical centers. It is necessary to establish a dynamic patient assessment and management system
to identify patients who need priority fertility treatment during epidemic control. Female Patients were assigned
as grade A and required hospitalization in the inpatient ward after egg retrieval. Patients who underwent controlled
ovarian stimulation were classified as grade B, and they can choose to be hospitalizedat home according to their own convenience. Patients undergoing frozen embryo transfer (FET) cycle or planned downregulation with gonadotropin releasing hormone agonists were defined as grade C, who could continue the assisted reproductive technology (ART) treatment cycle with negative COVID-19 nucleic acid test and there was no fever or respiratory symptoms. This brief comment summarizes the working procedure of the reproductive medical center in the first hospital of Lanzhou University in China to minimize the probability of hospital infection and ensure the safe conduct of assisted reproductive technology therapy.


Main Subjects

  1. Alsharif W, Qurashi A. Effectiveness of COVID-19 diagnosis and management tools: a review. Radiography (Lond). 2021; 27(2): 682-687.
  2. Lopez Bernal J, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, et al. Effectiveness of Covid-19 vaccines against the B.1.617.2 (Delta) Variant. N Engl J Med. 2021; 385(7): 585-594.
  3. Shiehzadegan S, Alaghemand N, Fox M, Venketaraman V. Analysis of the delta variant B.1.617.2 COVID-19. Clin Pract. 2021; 11(4): 778-784.
  4. Callaway E. Heavily mutated Omicron variant puts scientists on alert. Nature. 2021; 600(7887): 21.
  5. Anifandis G, Taylor TH, Messini CI, Chatzimeletiou K, Daponte A, Ioannou D, et al. The impact of SARS-CoV-2 on sperm cryostorage, theoretical or real risk? Medicina (Kaunas). 2021; 57(9): 946.
  6. Wang D, Hu B, Hu C. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020; 323(11): 1061-1069.
  7. Alteri A, Pisaturo V, Somigliana E, Viganò P. Cryopreservation in reproductive medicine during the COVID-19 pandemic: rethinking policies and European safety regulations. Hum Reprod. 2020; 35(12): 2650-2657.
  8. Anifandis G, Messini CI, Simopoulou M, Sveronis G, Garas A, Daponte A, et al. SARS-CoV-2 vs. human gametes, embryos and cryopreservation. Syst Biol Reprod Med. 2021; 67(4): 260-269.
  9. Paoli D, Pallotti F, Nigro G, Aureli A, Perlorca A, Mazzuti L, et al. Sperm cryopreservation during the SARS-CoV-2 pandemic. J Endocrinol Invest. 2021; 44(5): 1091-1096.
  10. Anifandis G, Messini CI, Daponte A, Messinis IE. COVID-19 and fertility: a virtual reality. Reprod Biomed Online. 2020; 41(2): 157-159.